Rakovina Therapeutics Inc. (TSXV:RKV)

Canada flag Canada · Delayed Price · Currency is CAD
0.6800
+0.0800 (13.33%)
Jul 23, 2025, 4:00 PM EDT
13.33%
Market Cap14.38M
Revenue (ttm)n/a
Net Income (ttm)-5.50M
Shares Out21.15M
EPS (ttm)-0.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18,800
Average Volume107,633
Open0.6800
Previous Close0.6000
Day's Range0.6500 - 0.6800
52-Week Range0.4000 - 2.3000
Beta-0.12
RSI50.11
Earnings DateAug 29, 2025

About Rakovina Therapeutics

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Varia... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mads Daugaard
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol RKV
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.